synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Management == Counseling and some medication, such as certain stimulants (e.g., lisdexamfetamine), selective serotonin reuptake inhibitors (SSRIs), and GLP-1 receptor agonists, may help people with BED. Some recommend a multidisciplinary approach in the treatment of the disorder.
This tendency to reduce surface energy in the system can be counteracted by adding species which will adsorb to the surface of the nanoparticles and lowers the activity of the particle surface thus preventing particle agglomeration according to the DLVO theory and preventing growth by occupying attachment sites for metal atoms. Chemical species that adsorb to the surface of nanoparticles are called ligands. Some of these surface stabilizing species are: NaBH4 in large amounts, polyvinylpyrrolidone (PVP), sodium dodecyl sulfate (SDS), and/or dodecanethiol. Once the particles have been formed in solution they must be separated and collected. There are several general methods to remove nanoparticles from solution, including evaporating the solvent phase or the addition of chemicals to the solution that lower the solubility of the nanoparticles in the solution. Both methods force the precipitation of the nanoparticles.
While giving evidence under oath, former Post Office chairman Henry Staunton tells a parliamentary hearing on the Horizon IT scandal that current Post Office chair Nick Read is under internal investigation. 28 February The Duke of Sussex loses a High Court challenge against the UK government's decision to downgrade his security status when he stopped being a working royal. A study in the British Medical Journal links ultra-processed foods to 32 negative health impacts, including a higher risk of heart disease, cancer, type 2 diabetes, adverse mental health and early death. Following a trial at the High Court in Glasgow, Iain Packer is found guilty of the April 2005 murder of Emma Caldwell, a sex worker whose body was found in woods five weeks after she disappeared from Glasgow. Packer, who is also convicted of 32 other offences against women, including rapes and sexual assaults, is sentenced to at least 36 years in prison, the second longest prison sentence to be handed out by a Scottish court. 29 February 2024 Rochdale by-election: In an unusually chaotic by-election, former MP George Galloway resoundingly wins for the Workers Party of Britain, marking his return to parliament. Independent candidate David Tully comes second, with the Conservative candidate Paul Ellison coming third. Both the Labour and Green Party candidates were disowned by their respective parties. Angiolini Inquiry: The public inquiry into the murder of Sarah Everard finds that her killer Wayne Couzens should never have been a police officer, and that opportunities to detect his offending were missed.
=== Fish === Lungs are found in three groups of fish; the coelacanths, the bichirs and the lungfish. Like in tetrapods, but unlike fish with swim bladder, the opening is at the ventral side of the oesophagus. The coelacanth has a nonfunctional and unpaired vestigial lung surrounded by a fatty organ. Bichirs, the only group of ray-finned fish with lungs, have a pair which are hollow unchambered sacs, where the gas-exchange occurs on very flat folds that increase their inner surface area. The lungs of lungfish show more resemblance to tetrapod lungs. There is an elaborate network of parenchymal septa, dividing them into numerous respiration chambers. In the Australian lungfish, there is only a single lung, albeit divided into two lobes. Other lungfish, however, have traditionally been considered having two lungs, but newer research defines paired lungs as bilateral lung buds that arise simultaneously and are both connected directly to the foregut, which is only seen in tetrapods. In all lungfish, including the Australian, the lungs are located in the upper dorsal part of the body, with the connecting duct curving around and above the oesophagus. The blood supply also twists around the oesophagus, suggesting that the lungs originally evolved in the ventral part of the body, as in other vertebrates.
Sources: en.wikipedia.org
The first woman elected president of a country was Vigdís Finnbogadóttir of Iceland, who won the 1980 presidential election as well as three subsequent elections, remaining in office for a total of 16 years, which makes her the longest-serving non-hereditary female head of state in history. Vigdís was also the first woman to win a presidential election where the second place candidate was another woman: she defeated Sigrún Þorsteinsdóttir in the 1988 presidential election. The first democratically elected female prime minister of a Muslim majority country was Benazir Bhutto of Pakistan, who led her party to victory in the 1988 general election and later in 1993, making her the first woman democratically elected leader of any Muslim nation. Bhutto was also the first of only two non-hereditary female world leaders who gave birth to a child while serving in office, the other being Jacinda Ardern of New Zealand. The longest-tenured female non-hereditary head of government is Sheikh Hasina of Bangladesh. She served as the country's prime minister from June 1996 to July 2001 and again from January 2009 until August 2024, for a combined total of over 20 years. Finland was the first republic in which women served concurrently as both the head of state and head of government, with both Anneli Jäätteenmäki and Mari Kiviniemi serving as prime ministers under president Tarja Halonen.
Yin and yang are universal aspects all things can be classified under, this includes diseases in general as well as the Eight Principles' first three couples. For example, cold is identified to be a yin aspect, while heat is attributed to yang. Since descriptions of patterns in terms of yin and yang lack complexity and clinical practicality, though, patterns are usually not labeled this way anymore. Exceptions are vacuity-cold and repletion-heat patterns, who are sometimes referred to as "yin patterns" and "yang patterns" respectively. Exterior (表; biǎo) refers to a disease manifesting in the superficial layers of the body – skin, hair, flesh, and meridians. It is characterized by aversion to cold and/or wind, headache, muscle ache, mild fever, a "floating" pulse, and a normal tongue appearance. Interior (里; lǐ) refers to disease manifestation in the zàng-fǔ, or (in a wider sense) to any disease that can not be counted as exterior. There are no generalized characteristic symptoms of interior patterns, since they'll be determined by the affected zàng or fǔ entity. Cold (寒; hán) is generally characterized by aversion to cold, absence of thirst, and a white tongue fur. More detailed characterization depends on whether cold is coupled with vacuity or repletion. Heat (热; rè) is characterized by an absence of aversion to cold, a red and painful throat, a dry tongue fur and a rapid and floating pulse if it falls together with an exterior pattern. In all other cases, symptoms depend on whether heat is coupled with vacuity or repletion.
The downregulation of ALAS1 lowers the levels of neurotoxic intermediates that cause AHP symptoms. Years of research have led to a greater understanding of siRNA therapies beyond those affecting the liver. As of 2019, Alnylam Pharmaceuticals was involved in therapies that may treat amyloidosis and CNS disorders like Huntington's disease and Alzheimer's disease. They have also partnered with Regeneron Pharmaceuticals to develop therapies for CNS, eye, and liver diseases. As of 2020, Onpattro and Givlaari were available for commercial application, and two siRNAs, lumasiran (ALN-GO1) and inclisiran, have been submitted for new drug application to the FDA. Several siRNAs are undergoing phase 3 clinical studies, and more candidates are in the early developmental stage. In 2020, Alnylam and Vir Pharmaceuticals announced a partnership and have started working on an RNAi therapy that would treat severe cases of COVID-19. Other companies that have had success in developing a pipeline of siRNA therapies include Dicerna Pharmaceuticals, partnered with Eli Lilly and Company, and Arrowhead Pharmaceuticals, partnered with Johnson and Johnson. Several other large pharmaceutical companies, such as Amgen and AstraZeneca, have also invested heavily in siRNA therapies, seeing potential success in this area of biological drugs.
Sources: en.wikipedia.org
=== Sources === Kosak, Dave (April 1, 2001). "Action Half-Life: Behind the Scenes". GameSpy. Retrieved 2017-07-04. Smith, Quintin (May 29, 2008). "3 – 2 – 1… Action Half-life". Rock, Paper, Shotgun. Retrieved 2017-07-04. Meer, Alec (June 8, 2009). "Action Half-Life 2: The Sauce Of Death". Rock, Paper, Shotgun. Retrieved 2017-07-04. Smith, Quintin (March 31, 2010). "Action Half-Life: The 5 a.m." Rock, Paper, Shotgun. Retrieved 2017-07-04. Smith, Quintin (May 23, 2011). "Stop, Drop, Roll: Action Half-Life 2 V2 Out". Rock, Paper, Shotgun. Retrieved 2017-07-04. Smith, Graham (May 8, 2014). "Total Converts: Unpotting The History Of Half-Life Modding". Rock, Paper, Shotgun. Retrieved 2017-07-04.
=== DNA hydrolysis === DNase agar is used to test whether a microbe can produce the exoenzyme deoxyribonuclease (DNase), which hydrolyzes DNA. Methyl green is used as an indicator in the growth medium because it is a cation that provides an opaqueness to a medium with the presence of negatively charged DNA strands. When DNA is cleaved, the media becomes clear, showing the presence of DNase activity. DNA hydrolysis is tested by growing an organism on a DNase Test Agar plate (providing nutrients and DNA) and then checking the plate for hydrolysis. The agar plate has DNA-methyl green complex, and if the organism on the agar does hydrolyze DNA then the green color fades and the colony is surrounded by a colorless zone.
The involvement of the king's son-in-law Iñaki Urdangarín in the corruption scandal known as the Nóos affair caused enormous damage to the image of the monarchy, as polls immediately reflected. The first official reaction of the Casa del Rey came on December 12, 2011, when it was decided to remove Urdangarín from official acts due to his "non-exemplary" behavior. In the Christmas Message the king spoke of "justice being equal for all". Four days later, Urdangarín was charged and between Saturday 25 and Sunday February 26, 2012, he had to testify before the judge in Palma de Mallorca. Another hard blow to the prestige of the monarchy came two months later, when on April 14, 2012, it was learned that King Juan Carlos had broken his hip on an elephant hunt in Botswana and that he had been rushed to Madrid for surgery. The news sparked a huge controversy that forced the king to apologize when he left the clinic. "I am very sorry. I made a mistake and it won't happen again," he said. On November 21, 2013, the king underwent another hip operation. It was the third surgery in less than a year, and the ninth in the last five. At the first official act in which he intervened, the celebration of Pascua Militar on January 6, 2014, he appeared tired and unwell. Just one day later, the judge of the Nóos affair, José Castro Aragón, charged the infanta Cristina de Borbón for the second time – the first had been dismissed the previous year by the Audiencia de Palma – for money laundering and tax crimes.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.